Volume 10 Supplement 1
Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
© Sawhney and Aggarwal; licensee BioMed Central Ltd. 2012
Published: 13 July 2012
Systemic onset JIA (SJIA) is a common subcategory of JIA in India and often difficult to treat. Tocilizumab (Actemra), an IL 6 blocker has been shown to be effective in children with SJIA. The drug is available in India for over a year. We have a high burden of infectious diseases here and biologics are therefore used judiciously. We used the drug in SJIA patients to test the efficacy, tolerability and side effect profile.
Prospective study on the use of Tociluzimab in SJIA patients. Inclusion criteria: All children with SJIA more than three years of age who had persistent disease activity in spite of adequate NSAID, steroids and DMARDs for at least three months. Exclusion criteria: Presence of any active infection specifically tuberculosis.
Mean Hb gm%
Mean ESR mm/hr
Mean platelet /mm3
Pts on pred
With careful screening Tocilizumab can be used safely in areas that have a high burden of infections.The systemic features, haemoglobin and ESR respond rapidly, the arthritis responds later. Some children continue to have active disease inspite of this intervention.
Sujata Sawhney: None; Manjari Aggarwal: None.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.